Cirrhosis NASH Trials
Age – Adult (18-85)
Gender – Female, Male
Disease Type – Cirrhosis Hepatic Encephalopathy
Phase – 3
Length -72 weeks
Compensation available.
Inclusion:
– Cirrhosis with Hepatic Encephalopathy
– Medically controlled ascites or no ascites present
– West Haven Criteria <2
– Males and non-pregnant females
Exclusion:
– Allergy to Rifaximin, rifampin, rifamycin antimicrobial agent
– Receiving dialysis
– Active Cancer diagnosis
Salix RNLC3131: A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin SSD-40mg IR for the delay of the first episode of overt hepatic encephalopathy (OHE) decompensation in liver cirrhosis, defined by the presence of medically controlled ascites.
Age – Adult (18-85)
Gender – Female, Male
Disease Type – Cirrhosis Hepatic Encephalopathy
Phase – 3
Length -72 weeks
Compensation available.
Inclusion:
– Cirrhosis Medically controlled ascites
– West Haven Criteria <2
– Males and non-pregnant females
Exclusion:
– Allergy to Rifaximin, rifampin, rifamycin antimicrobial agent
– Receiving dialysis
– Active Cancer diagnosis
MGL-3196-19: A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on Liver-related Outcomes in Patients with Well-compensated (Child-Pugh A) Non-alcoholic Steatohepatitis (NASH) Cirrhosis (MAESTRO-NASH OUTCOMES)
Learn More
Additional Information
For more information on what current clinical trials are available at Kansas City Research Institute or additional information and how to get involved, please contact our office phone at (816)759-2574 or send by email at study@kcresearchinstitute.com.